TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Need for a fourth injection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: perinatal HIV-1 transmission
Endpoint domain: Mortality/survival
Primary endpoint: HSV shedding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: EC50 of remifentanil for maintaining hemodynamic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiac death, myocardial infarction related to the target vessel, or target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: HIV‐1 RNA levels of less than 50 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic failure
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge of physicians' compensation models
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trust in primary care physicians
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Loyalty to physician group
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Myocardial 11C‐hydroxyephedrine retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events experienced by participants
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in supragingival dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingivitis severity index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingival bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular concentrations of dihydroxyphenylacetic acid (DOPAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular concentrations of homovanillic acid (HVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular concentrations of 5-hydroxyindoleacetic acid (5-HIAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collateral flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG ST-segment shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fraction of patients free from angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: APACHEII score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aepEX values during anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Number of deaths
Endpoint domain: Mortality/survival
Primary endpoint: Breathlessness at least once a week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cervical lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior head translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness handicap inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalization of ACTH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of salivary cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of serum cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Severe cord infection
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in FMA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in spasticity (MAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in muscle coordination (EMG co-contraction indexes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liquid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial salvage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ejection fraction after 3 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thrombolysis in Myocardial Infarction flow grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: immediate dental pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clearance of psoriasis lesions (DSS = 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immune reconstitution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of remission
Endpoint domain: Mortality/survival
Primary endpoint: impact of headache on patients' lives
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in pigmentation of macular amyloidosis patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: remission rate after 104 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate after 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health-related quality of life (HRQL) improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative hospital stay time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: VAS scores of neck comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEFR percentage predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily variability of PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in morning stiffness duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in disease management knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of Metabolic Syndrome (MetS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of Metabolic Syndrome (MetS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Freedom from symptomatic paroxysmal AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: remission of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of scalp psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement to clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer ratios (GMT ratios)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intensity and frequency of De Qi characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MASS De Qi Index (MDI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in health and well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Independence of patients after discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative surgical site infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: ADP-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in probing depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cholesterol (TC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-Density Lipoprotein Cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arteriosclerotic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: wheeze with breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: wheeze without a cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: asthma attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hayfever and nasal allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensitization to grass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: event-free survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: A1C levels at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma MDA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HLA DR expression by conjunctival cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD40 expression in eyes with KCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fas expression in eyes with KCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reversal of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: social function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Estimated 10-year CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IFNalpha plasma activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BAFF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma and erythrocyte folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Appetite improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain-free walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb muscle mass (LM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants with depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratios of Bacteroides‐Prevotella‐Porphyromonas group to Firmicutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function of dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normalizing rates of ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalizing rates of HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venipunctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multiple puncture attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of procollagen 1 and 3 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Expression of heat shock protein (HSP) 47
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SF-36 physical functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-reported physical functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: physical activity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: falls
Endpoint domain: Adverse events/effects
Primary endpoint: skin sores
Endpoint domain: Adverse events/effects
Primary endpoint: Nottingham Extended Activities of Daily Living score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologically demonstrable signs of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color change values (ΔE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MADRS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalization for congestive heart failure (CHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic Syndrome (MetS) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: wet desquamation of the axillary skin
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial-venous difference in oxygen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of lactic acid in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average increase in myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the triazolam concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half‐life of triazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of triazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childbirth Experience Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detectable PPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median APAP-CYS concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Accelerated treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin levels at nadir after second cycle of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: decrease in delusion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of self-reflectiveness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VAS scores at 0 min and 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement for analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first analgesia dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PNE reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h mean heart rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SDNN increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spiritual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Death anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AMH level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of oxygen of the jugular venous bulb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net cerebral lactate efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Return to work effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of the MRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor 1 'HOT FLUSHES' score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor 2 'PSYCHE' score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erectile response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stereotypic behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Scale evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in analyzing the entire lung
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endogenous glucose production rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urea excretion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose uptake and oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: anxiety and depression improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client Satisfaction Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative agitation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pelvic floor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Likelihood of smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PCO 2 years after phacoemulsification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mivacurium infusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous recovery time from T1=10% to TOF ratio=0.7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of images considered perfect or almost perfect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative shoulder pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative upper abdominal pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes